Drugs / RTS,S/AS01E
last change Dec 2014 re-read 2 minutes ago

RTS,S/AS01E

Vaccine

Developed for
malaria
Investigated by
GlaxoSmithKline · The PATH Malaria Vaccine Initiative (MVI)

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01231503 Jan 2011 → Apr 2014 malaria GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RTS,S/AS01E “Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age.” NCT01231503
Modality Vaccine “experimental malaria vaccineNCT01231503
Route Intramuscular “The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh.” NCT01231503